Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors
The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahip...
Gespeichert in:
Veröffentlicht in: | Pharmacology, biochemistry and behavior biochemistry and behavior, 1998-08, Vol.60 (4), p.879-887 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 887 |
---|---|
container_issue | 4 |
container_start_page | 879 |
container_title | Pharmacology, biochemistry and behavior |
container_volume | 60 |
creator | Bitran, Daniel Shiekh, Michael Dowd, Jennifer A. Dugan, Matthew M. Renda, Phyllis |
description | The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses. |
doi_str_mv | 10.1016/S0091-3057(98)00071-9 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80060661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091305798000719</els_id><sourcerecordid>80060661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-46f5319bf912a472535849c0deb05d331c646371da7e9a3ea233166ef58f9b233</originalsourceid><addsrcrecordid>eNqFkcFvFCEYxYnR1G31T2jCwZj2MArDDAwnUzetbVKjaeuZsMxHis4MIx_btCf_denuZq89EXi_xwfvEXLM2SfOuPx8y5jmlWCtOtHdKWNM8Uq_IgveKVG1XKnXZLFH3pJDxN8FamqpDsiBVkVS9YL8W8aUg4uYIcUJ6BXSn5DGgBgegOZI8z3Qs-kxxOGpcPTce3CZ3t3bTG8A10NGepHiuOG-DtH9sT3Q6OllmOfo7DjbgX4PEyRbxO2s0BergznHhO_IG28HhPe79Yj8uji_W15W1z--XS3PrivX1CxXjfSt4HrlNa9to-pWtF2jHethxdpeCO5kI4XivVWgrQBblzMpwbed16uyOSIft_fOKf5dA2ZT_uhgGOwEcY2mY0wyKfmLIFcNb0qiBWy3oEsRMYE3cwqjTU-GM_PckNk0ZJ7jN7ozm4aMLr7j3YD1aoR-79pVUvQPO92is4NPdnIB91gtOl64gn3ZYlBSewiQDLoAk4M-pNKQ6WN44SH_Aa3_rcc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17414057</pqid></control><display><type>article</type><title>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</title><source>ScienceDirect</source><source>MEDLINE</source><creator>Bitran, Daniel ; Shiekh, Michael ; Dowd, Jennifer A. ; Dugan, Matthew M. ; Renda, Phyllis</creator><creatorcontrib>Bitran, Daniel ; Shiekh, Michael ; Dowd, Jennifer A. ; Dugan, Matthew M. ; Renda, Phyllis</creatorcontrib><description>The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses.</description><identifier>ISSN: 0091-3057</identifier><identifier>EISSN: 1873-5177</identifier><identifier>DOI: 10.1016/S0091-3057(98)00071-9</identifier><identifier>PMID: 9700972</identifier><identifier>CODEN: PBBHAU</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adrenalectomy ; Adult and adolescent clinical studies ; Animals ; Anti-Anxiety Agents - pharmacology ; Anti-Inflammatory Agents - pharmacology ; Anxiety - psychology ; Anxiety disorders. Neuroses ; Biological and medical sciences ; Corticosterone - pharmacology ; Cortisone - blood ; Defensive burying ; Dexamethasone - pharmacology ; Elevated plus-maze ; Hippocampus - drug effects ; Hippocampus - metabolism ; Male ; Medical sciences ; Microinjections ; Mifepristone - pharmacology ; Mineralocorticoid Receptor Antagonists - pharmacology ; Miscellaneous ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Rats ; Receptors, Glucocorticoid - antagonists & inhibitors ; RU 28318 ; RU 38486 ; Spironolactone - administration & dosage ; Spironolactone - analogs & derivatives ; Spironolactone - pharmacology ; Thigmotaxis</subject><ispartof>Pharmacology, biochemistry and behavior, 1998-08, Vol.60 (4), p.879-887</ispartof><rights>1998 Elsevier Science Inc.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-46f5319bf912a472535849c0deb05d331c646371da7e9a3ea233166ef58f9b233</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0091-3057(98)00071-9$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2381097$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9700972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bitran, Daniel</creatorcontrib><creatorcontrib>Shiekh, Michael</creatorcontrib><creatorcontrib>Dowd, Jennifer A.</creatorcontrib><creatorcontrib>Dugan, Matthew M.</creatorcontrib><creatorcontrib>Renda, Phyllis</creatorcontrib><title>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</title><title>Pharmacology, biochemistry and behavior</title><addtitle>Pharmacol Biochem Behav</addtitle><description>The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses.</description><subject>Adrenalectomy</subject><subject>Adult and adolescent clinical studies</subject><subject>Animals</subject><subject>Anti-Anxiety Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anxiety - psychology</subject><subject>Anxiety disorders. Neuroses</subject><subject>Biological and medical sciences</subject><subject>Corticosterone - pharmacology</subject><subject>Cortisone - blood</subject><subject>Defensive burying</subject><subject>Dexamethasone - pharmacology</subject><subject>Elevated plus-maze</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microinjections</subject><subject>Mifepristone - pharmacology</subject><subject>Mineralocorticoid Receptor Antagonists - pharmacology</subject><subject>Miscellaneous</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Rats</subject><subject>Receptors, Glucocorticoid - antagonists & inhibitors</subject><subject>RU 28318</subject><subject>RU 38486</subject><subject>Spironolactone - administration & dosage</subject><subject>Spironolactone - analogs & derivatives</subject><subject>Spironolactone - pharmacology</subject><subject>Thigmotaxis</subject><issn>0091-3057</issn><issn>1873-5177</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFvFCEYxYnR1G31T2jCwZj2MArDDAwnUzetbVKjaeuZsMxHis4MIx_btCf_denuZq89EXi_xwfvEXLM2SfOuPx8y5jmlWCtOtHdKWNM8Uq_IgveKVG1XKnXZLFH3pJDxN8FamqpDsiBVkVS9YL8W8aUg4uYIcUJ6BXSn5DGgBgegOZI8z3Qs-kxxOGpcPTce3CZ3t3bTG8A10NGepHiuOG-DtH9sT3Q6OllmOfo7DjbgX4PEyRbxO2s0BergznHhO_IG28HhPe79Yj8uji_W15W1z--XS3PrivX1CxXjfSt4HrlNa9to-pWtF2jHethxdpeCO5kI4XivVWgrQBblzMpwbed16uyOSIft_fOKf5dA2ZT_uhgGOwEcY2mY0wyKfmLIFcNb0qiBWy3oEsRMYE3cwqjTU-GM_PckNk0ZJ7jN7ozm4aMLr7j3YD1aoR-79pVUvQPO92is4NPdnIB91gtOl64gn3ZYlBSewiQDLoAk4M-pNKQ6WN44SH_Aa3_rcc</recordid><startdate>19980801</startdate><enddate>19980801</enddate><creator>Bitran, Daniel</creator><creator>Shiekh, Michael</creator><creator>Dowd, Jennifer A.</creator><creator>Dugan, Matthew M.</creator><creator>Renda, Phyllis</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7X8</scope></search><sort><creationdate>19980801</creationdate><title>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</title><author>Bitran, Daniel ; Shiekh, Michael ; Dowd, Jennifer A. ; Dugan, Matthew M. ; Renda, Phyllis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-46f5319bf912a472535849c0deb05d331c646371da7e9a3ea233166ef58f9b233</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adrenalectomy</topic><topic>Adult and adolescent clinical studies</topic><topic>Animals</topic><topic>Anti-Anxiety Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anxiety - psychology</topic><topic>Anxiety disorders. Neuroses</topic><topic>Biological and medical sciences</topic><topic>Corticosterone - pharmacology</topic><topic>Cortisone - blood</topic><topic>Defensive burying</topic><topic>Dexamethasone - pharmacology</topic><topic>Elevated plus-maze</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microinjections</topic><topic>Mifepristone - pharmacology</topic><topic>Mineralocorticoid Receptor Antagonists - pharmacology</topic><topic>Miscellaneous</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Rats</topic><topic>Receptors, Glucocorticoid - antagonists & inhibitors</topic><topic>RU 28318</topic><topic>RU 38486</topic><topic>Spironolactone - administration & dosage</topic><topic>Spironolactone - analogs & derivatives</topic><topic>Spironolactone - pharmacology</topic><topic>Thigmotaxis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bitran, Daniel</creatorcontrib><creatorcontrib>Shiekh, Michael</creatorcontrib><creatorcontrib>Dowd, Jennifer A.</creatorcontrib><creatorcontrib>Dugan, Matthew M.</creatorcontrib><creatorcontrib>Renda, Phyllis</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology, biochemistry and behavior</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bitran, Daniel</au><au>Shiekh, Michael</au><au>Dowd, Jennifer A.</au><au>Dugan, Matthew M.</au><au>Renda, Phyllis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors</atitle><jtitle>Pharmacology, biochemistry and behavior</jtitle><addtitle>Pharmacol Biochem Behav</addtitle><date>1998-08-01</date><risdate>1998</risdate><volume>60</volume><issue>4</issue><spage>879</spage><epage>887</epage><pages>879-887</pages><issn>0091-3057</issn><eissn>1873-5177</eissn><coden>PBBHAU</coden><abstract>The effects of RU 28318, a mineralocorticoid receptor antagonist (A-MR), and RU 38486, a glucocorticoid receptor antagonist (A-GR) on behavior in three animal models of anxiety were assessed after microinjection into the dorsal hippocampus. Significant anxiolytic effects were observed after intrahippocampal injection of 0.5, and 1 ng of A-MR in thigmotaxic behavior in the open field, in the elevated plus-maze, and in the defensive burying test. Lower (0.2 ng) or higher (5 ng) doses of A-MR were ineffective, as were comparable injections of A-GR or microinjections of combined A-MR and A-GR. The anxiolytic effect of intrahippocampal A-MR administration observed in the elevated plus-maze and in the open field was not observed in adrenalectomized animals or in animals pretreated with a systemic injection of dexamethasone (80 mg/kg). Intrahippocampal injection of 1 ng of A-MR or A-GR prevented the return to basal corticosterone levels observed 90 min after restraint stress. This effect was reversed in dexamethasone-pretreated animals. The results are discussed in light of recent findings implicating the role of the MR in the hippocampus in adaptive behavioral responses to an aversive or threatening environment, and further implicate the permissive role of corticosterone in A-MR-induced behavioral responses.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>9700972</pmid><doi>10.1016/S0091-3057(98)00071-9</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0091-3057 |
ispartof | Pharmacology, biochemistry and behavior, 1998-08, Vol.60 (4), p.879-887 |
issn | 0091-3057 1873-5177 |
language | eng |
recordid | cdi_proquest_miscellaneous_80060661 |
source | ScienceDirect; MEDLINE |
subjects | Adrenalectomy Adult and adolescent clinical studies Animals Anti-Anxiety Agents - pharmacology Anti-Inflammatory Agents - pharmacology Anxiety - psychology Anxiety disorders. Neuroses Biological and medical sciences Corticosterone - pharmacology Cortisone - blood Defensive burying Dexamethasone - pharmacology Elevated plus-maze Hippocampus - drug effects Hippocampus - metabolism Male Medical sciences Microinjections Mifepristone - pharmacology Mineralocorticoid Receptor Antagonists - pharmacology Miscellaneous Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Rats Receptors, Glucocorticoid - antagonists & inhibitors RU 28318 RU 38486 Spironolactone - administration & dosage Spironolactone - analogs & derivatives Spironolactone - pharmacology Thigmotaxis |
title | Corticosterone Is Permissive to the Anxiolytic Effect That Results From the Blockade of Hippocampal Mineralocorticoid Receptors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A42%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Corticosterone%20Is%20Permissive%20to%20the%20Anxiolytic%20Effect%20That%20Results%20From%20the%20Blockade%20of%20Hippocampal%20Mineralocorticoid%20Receptors&rft.jtitle=Pharmacology,%20biochemistry%20and%20behavior&rft.au=Bitran,%20Daniel&rft.date=1998-08-01&rft.volume=60&rft.issue=4&rft.spage=879&rft.epage=887&rft.pages=879-887&rft.issn=0091-3057&rft.eissn=1873-5177&rft.coden=PBBHAU&rft_id=info:doi/10.1016/S0091-3057(98)00071-9&rft_dat=%3Cproquest_cross%3E80060661%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17414057&rft_id=info:pmid/9700972&rft_els_id=S0091305798000719&rfr_iscdi=true |